美托洛尔联合曲美他嗪治疗冠心病心力衰竭的疗效及安全性分析

The Efficacy and Safety of Metoprolol Combined with Trimetazidine in the Treatment of Coronary Heart Disease and Heart Failure

目的对美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床治疗效果及安全性进行分析。方法方便选取2017年8月-2019年8月于该院接受治疗的冠心病心力衰竭患者110例,通过随机法分为55例对照组(常规内科治疗)与55例研究组(美托洛尔联合曲美他嗪治疗),比较不同治疗方法临床效果与安全性。结果经过对比后,两组患者治疗前炎症因子相关指标差异无统计学意义(t=0.470、1.066、0.342, P>0.05);相较于对照组,研究组IL-6、TNF-α、hs-CRP水平更低,差异有统计学意义(t=11.022、18.322、17.057,P<0.05)。两组患者治疗前心功能相关指标差异无统计学意义(t=0.487、0.969、0.153,P>0.05);较于对照组,研究组LVEF、LVEDD、LVESD水平更低,差异有统计学意义(t=10.221、8.016、5.940,P<0.05)。对照组不良反应发生率为16.4%,研究组不良反应发生率为5.5%,相较于对照组,研究组不良反应发生率更低,差异有统计学意义(χ^2=6.092,P<0.05)。结论在冠心病心力衰竭临床治疗中,可通过美托洛尔联合曲美他嗪进行治疗,可使炎症反应降低,改善心功能,减少不良反应发生情况,具备较高临床价值。

Objective To analyze the clinical efficacy and safety of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure.Methods Convenient select 110 patients with coronary heart disease and heart failure who were treated in our hospital from August 2017 to August 2019 were randomly divided into 55 cases in the control group(conventional medical treatment)and 55 cases in the study groups(metoprolol and trimetazidine treatment).To compare the clinical effect and safety of different treatment methods.Results After comparison,the differences in inflammatory factor-related indicators before treatment between the two groups were small(t=0.470,1.066,0.342,P>0.05);compared with the control group,the IL-6,TNF-α,and hs-CRP of the study group were lower(t=11.022,18.322,17.057,P<0.05).The differences in cardiac function-related indicators before treatment between the two groups were small(t=0.487,0.969,0.153,P>0.05).Compared with the control group,the levels of LVEF,LVEDD,and LVESD in the study group were lower(t=10.221,8.016,5.940,P<0.05).The incidence of adverse reactions in the control group was 16.4%,and the incidence of adverse reactions in the study group was 5.5%.Compared with the control group,the incidence of adverse reactions in the study group was lower(χ^2=6.092,P<0.05).Conclusion In the clinical treatment of coronary heart disease and heart failure,it can be treated by metoprolol combined with trimetazidine,which can reduce the inflammatory response,improve cardiac function,reduce the occurrence of adverse reactions,and has high clinical value.